Everolimus
Back to searchMolecule Structure
Scientific Name
Everolimus
Description of the Drug
Everolimus is a mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-02-07 from
http://www.drugbank.ca/drugs/DB01590
http://www.drugbank.ca/drugs/DB01590
Brand Name(s)
Afinitor, Afinitor disperz, Certican, Votubia, Zortress
Company Owner(s)
Mylan Pharmaceuticals Inc, Hikma Pharmaceuticals Usa Inc, Par Pharmaceutical, Novartis Pharmaceutical Corp, Novartis Pharmaceuticals Corp, Biocon Pharma Ltd, Breckenridge Pharmaceutical Inc, Teva Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| FK506-binding protein 1A | SINGLE PROTEIN | INHIBITOR | CHEMBL1902 |
Clinical Trial(s)
Unichem Links
| Atlas | RAD001 | ||
| SureChEMBL | SCHEMBL20973097 | SCHEMBL4378 | |
| PharmGKB | PA164746311 | ||
| DrugBank | DB01590 | ||
| PubChem: Thomson Pharma | 14767667 | 14865574 | |
| PubChem | 6442177 | ||
| LINCS | LSM-43172 | ||
| EPA CompTox Dashboard | DTXSID0040599 | ||
| DrugCentral | 1118 | ||
| ChemicalBook | CB9502411 | ||
| Guide to Pharmacology | 5889 | ||
| GSRS | c3be78ca-34b3-40df-8932-b66dab64bc69 | ||
| rxnorm | ZORTRESS | AFINITOR | EVEROLIMUS |
| PubChem: Drugs of the Future | 12014881 | ||
| ChEBI | 68478 | ||
| ZINC | ZINC000169677008 |
